PLoS ONE,
Journal Year:
2024,
Volume and Issue:
19(11), P. e0310751 - e0310751
Published: Nov. 18, 2024
Objective
Postpartum
depression
(PPD)
is
a
major
mental
health
issue
affecting
10%–15%
of
women
globally.
This
meta-analysis
synthesized
updated
evidence
on
sub-anesthetic
ketamine/esketamine’s
efficacy
in
preventing
PPD.
Methods
Randomized
controlled
trials
(RCTs)
comparing
ketamine/esketamine
to
placebo
for
PPD
prevention
were
searched
without
language
restriction.
Primary
outcomes
risk
at
1-
and
4–6-week
postpartum.
Secondary
included
the
difference
scores
adverse
events.
Trial
sequential
analysis
(TSA)
was
conducted
validate
reliability.
Results
A
22
RCTs
(n
=
3,463)
showed
that
significantly
decreased
(risk
ratio
[RR],
0.41;
95%
confidence
interval
[CI],
0.3–0.57)
(RR,
0.47;
95%CI,
0.35–0.63)
follow-ups.
Consistently,
participants
receiving
had
lower
depression-related
(standardized
mean
[SMD],
−0.94;
−1.26
−0.62)
(SMD,
−0.89;
−1.25
−0.53)
Despite
potential
publication
bias,
TSA
confirmed
evidence’s
Subgroup
preventive
effect
1-week
consistent,
regardless
administration
timing,
type
agents,
or
total
dosage
(<0.5
vs.
≥0.5
mg/kg).
For
period,
favorably
reduced
only
with
postoperative
use
esketamine,
having
no
observed
influence.
Participants
experienced
more
frequency
hallucinations
4.77;
1.39–16.44)
dizziness
1.36;
1.02–1.81).
Conclusion
Our
findings
advocate
low-dose
avert
PPD,
which
needed
additional
research
confirmation.
Neurobiology of Stress,
Journal Year:
2021,
Volume and Issue:
16, P. 100422 - 100422
Published: Dec. 14, 2021
Rapid
antidepressant
effects
of
S-ketamine
have
repeatedly
been
confirmed
in
patients
with
depression,
as
well
chronic
unpredictable
mild
stress
(CUMS)
animal
models.
However,
the
pharmacological
study
for
anti-postpartum
depression
has
not
considered.
In
this
study,
classical
method
reproductive
hormone
withdrawal
was
used
to
construct
a
rat
model
postpartum
(PPD).
Subsequently,
evaluated
low-dose
on
behavior
and
synaptic
plasticity,
which
is
related
hippocampus
PPD
rats.
Multiple
behavioral
tests
were
evaluate
depression-like
behaviors
Synaptic
plasticity
can
be
demonstrated
by
Western
blot,
Golgi
staining,
transmission
electron
microscopy,
electrophysiological
recording.
Our
provides
insight
into
role
antianxiety
indicates
that
maintaining
key
target
therapy
induced
withdrawal.
Medicine,
Journal Year:
2024,
Volume and Issue:
103(44), P. e40295 - e40295
Published: Nov. 1, 2024
Background:
The
aim
of
this
randomized,
double-blind
placebo-controlled
clinical
trial
was
to
study
the
effects
subclinical
doses
esketamine
on
postpartum
depression
and
pain
following
elective
cesarean
sections.
Methods:
This
included
150
pregnant
women
undergoing
After
umbilical
cord
clamping,
participants
received
either
(0.25
mg/kg,
diluted
in
10
mL
0.9%
saline)
or
a
placebo
(10
saline).
primary
outcome
measures
were
incidence
(PPD)
postoperative
pain.
Edinburgh
Postnatal
Depression
Scale
used
evaluate
PPD
days
3,
7,
14
postpartum,
with
an
score
≥
indicating
PPD.
Postoperative
assessed
using
Visual
Analog
(VAS)
at
4,
24,
48
hours
post-surgery.
Secondary
outcomes
adverse
reactions
Ramsay
sedation
scores
5
15
minutes
post-administration.
Results:
There
no
significant
differences
between
2
groups
(
P
>
.05).
VAS
showed
4
24
postoperatively
<
.05),
but
not
experimental
group
had
significantly
higher
post-administration
compared
control
observed
upon
leaving
operating
room
Conclusion:
Subclinical
did
reduce
lower
experienced
temporary
increases
shortly
after
administration.
PLoS ONE,
Journal Year:
2024,
Volume and Issue:
19(11), P. e0310751 - e0310751
Published: Nov. 18, 2024
Objective
Postpartum
depression
(PPD)
is
a
major
mental
health
issue
affecting
10%–15%
of
women
globally.
This
meta-analysis
synthesized
updated
evidence
on
sub-anesthetic
ketamine/esketamine’s
efficacy
in
preventing
PPD.
Methods
Randomized
controlled
trials
(RCTs)
comparing
ketamine/esketamine
to
placebo
for
PPD
prevention
were
searched
without
language
restriction.
Primary
outcomes
risk
at
1-
and
4–6-week
postpartum.
Secondary
included
the
difference
scores
adverse
events.
Trial
sequential
analysis
(TSA)
was
conducted
validate
reliability.
Results
A
22
RCTs
(n
=
3,463)
showed
that
significantly
decreased
(risk
ratio
[RR],
0.41;
95%
confidence
interval
[CI],
0.3–0.57)
(RR,
0.47;
95%CI,
0.35–0.63)
follow-ups.
Consistently,
participants
receiving
had
lower
depression-related
(standardized
mean
[SMD],
−0.94;
−1.26
−0.62)
(SMD,
−0.89;
−1.25
−0.53)
Despite
potential
publication
bias,
TSA
confirmed
evidence’s
Subgroup
preventive
effect
1-week
consistent,
regardless
administration
timing,
type
agents,
or
total
dosage
(<0.5
vs.
≥0.5
mg/kg).
For
period,
favorably
reduced
only
with
postoperative
use
esketamine,
having
no
observed
influence.
Participants
experienced
more
frequency
hallucinations
4.77;
1.39–16.44)
dizziness
1.36;
1.02–1.81).
Conclusion
Our
findings
advocate
low-dose
avert
PPD,
which
needed
additional
research
confirmation.
